A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-03-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: acutehoursinfusionpressurechronic
  Phrases that lowered it: participantschecktakevaluate theto evaluate
• Sponsor's past termination rate: 12.1% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports with a death: 13.2% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 39 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 495 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 18601 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 78.7% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 104459 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU) NCT00967499 · started 2009 · scored riskier than 24% of active trials completed
• Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV) NCT00895830 · started 2009 · scored riskier than 28% of active trials completed
• A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery NCT02542384 · started 2015 · scored riskier than 11% of active trials completed
• Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery NCT06904248 · started 2024 · scored riskier than 7% of active trials completed
• Phase II Dose-ranging Study of APD421 in PONV NCT01510704 · started 2012 · scored riskier than 24% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.